ReviewChinese medicine2025
Therapeutic potential of traditional Chinese medicine and mechanisms for the treatment of type 2 diabetes mellitus.
Review in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Linking Gut Microbiota, Mitochondrial Redox Dysfunction, and Ferroptosis in Cardiometabolic Diseases: A Narrative Review of Mechanistic Evidence and Redox-Targeted Interventions.Antioxidants (Basel, Switzerland) · 2026Review
- Diabetes affects the composition of the respiratory tract microbiome and transcriptome in patients with viral pneumonia.Microbiology spectrum · 2026Article
- Type 2 diabetes is associated with pulmonary cavitation in men with HIV-TB coinfection.Frontiers in endocrinology · 2026Article
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- Er-Chen Decoction ameliorates metabolic dysfunction-associated steatotic liver disease via gut microbiota-barrier axis-driven hepatic metabolic reprogramming.Frontiers in microbiology · 2026Article
- Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetes, a chronic metabolic non-communicable disease, has become prevalent worldwide. Its prevalence is increasing at an alarming rate, and the affected population is becoming increasingly younger, posing a serious threat to both individual health and social well-being. Notably, type 2 diabetes mellitus (T2DM) accounts for more than 90% of all diabetes cases, a statistic that underscores its dominant position in the disease burden. Despite substantial progress in the field of diabetes treatment, existing diabetes medications still fail to fully address the complex and pressing clinical needs of patients. Therefore, the development of new therapeutic drugs for T2DM is of crucial significance. Traditional Chinese medicine (TCM) has shown significant potential in alleviating the symptoms of T2DM and improving patients' quality of life, providing an effective complementary approach to conventional treatments. This study systematically clarifies and reviews the pathogenesis of T2DM from multiple dimensions, including inflammation, oxidative stress, ferroptosis, pyroptosis, necroptosis, autophagy, and gut microbiota. It also examines and summarizes TCM compound formulations and their main active ingredients that can improve the disease, and elucidates the disease-improving effects of these TCM ingredients targeting the aforementioned mechanisms. Studies have shown that TCM plays an important role in improving T2DM by targeting key mechanisms such as insulin resistance, β-cell damage, and glucose-lipid metabolism disorders. This not only provides valuable ideas and reference basis for researchers in endocrine basic research, pharmacologists, and clinicians to develop TCM with low toxicity and side effects but also opens up new research directions for the treatment of T2DM and lays a theoretical foundation for new drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.